$281 Million is the total value of Clarus Ventures, LLC's 8 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | ESSA Pharma Inc. | $0 | – | -33,371,212 | -100.0% | -6.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Nanostring Technologies Inc. | 20 | Q3 2018 | 60.2% |
| Sientra Inc. | 16 | Q3 2018 | 38.2% |
| Oxford Immunotex Global PLC | 14 | Q1 2017 | 17.4% |
| Catabasis Pharmaceuticals Inc. | 14 | Q3 2018 | 15.3% |
| VBI Vaccines Inc. | 10 | Q3 2018 | 11.4% |
| TetraLogic Pharmaceuticals Corporation | 9 | Q4 2015 | 12.5% |
| ESSA Pharma Inc. | 9 | Q1 2018 | 6.5% |
| Aerie Pharmaceuticals Inc. | 7 | Q4 2015 | 30.5% |
| VBI Vaccines Inc. | 7 | Q1 2016 | 9.1% |
| Ophthotech Corp | 6 | Q1 2015 | 31.5% |
View Clarus Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-15 |
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-14 |
| 13F-NT | 2023-08-14 |
| 13F-NT | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-15 |
| 13F-NT | 2022-05-16 |
| 13F-NT | 2022-02-14 |
View Clarus Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.